← Back to Search

H2 Receptor Antagonist

Famotidine 20 MG for Pulmonary Arterial Hypertension (REHAB-PH Trial)

Phase 2
Waitlist Available
Led By Peter J Leary, MD, PhD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved

Summary

This trial tests famotidine, a common heartburn medication, in adults with pulmonary arterial hypertension. The goal is to see if it can help the right side of the heart become stronger and work better under stress. Participants will take the medication for a period of time and have regular check-ups to monitor their heart function.

Eligible Conditions
  • Pulmonary Arterial Hypertension
  • Cor Pulmonale

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Six-minute Walk Distance
Secondary study objectives
Chang in Log-transformed BNP
Change in Health Related Quality of Life (emPHasis-10 Questionnaire)
Change in Right Ventricular Morphology by Echocardiogram (RV Dilation and TAPSE)
+2 more
Other study objectives
Cardiopulmonary Exercise Testing (Sub-study): Exercise
Cardiopulmonary Exercise Testing (Sub-study): Maximal Oxygen Uptake
Invasive Hemodynamics (Sub-study): Hemodynamics
+1 more

Side effects data

From 2023 Phase 2 trial • 80 Patients • NCT03554291
20%
Coronavirus, Influenza, Medical Device site infection, Ear infection, Metapneumovirus, Nasopharyngit
20%
Abdominal pain, dyspepsia, nausea, flatulence, discomfort
13%
Syncope, Dizziness, Headache, Dysgeusia, Encephalopathy
10%
dyspnea, hemoptysis, throat irritation
10%
angina, atrial flutter, cardiac failure
10%
Coronavirus, Medical Device Site Infection, Metapneumovirus, Pneumonia
10%
Atrial flutter, Angina Pectoris, Cardiac Failure
8%
syncope, encephalopathy
5%
dehydration, hypokalemia
5%
acute kidney injury,
5%
non-cardiac chest pain, swelling
5%
Dehydration, Hypokalemia
5%
Acute Kidney Injury
5%
Dyspnea, Hemoptysis
3%
hypotension
3%
Hypotension
3%
rash
3%
back pain, bursitis, neck pain
3%
vaginal hemorrhage
100%
80%
60%
40%
20%
0%
Study treatment Arm
Famotidine
Placebo

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: FamotidineExperimental Treatment1 Intervention
20mg of oral famotidine (pill) daily Other names: Pepcid
Group II: PlaceboPlacebo Group1 Intervention
Daily oral placebo (pill)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Famotidine
FDA approved

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,816 Previous Clinical Trials
1,914,268 Total Patients Enrolled
1 Trials studying Pulmonary Arterial Hypertension
60 Patients Enrolled for Pulmonary Arterial Hypertension
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,934 Previous Clinical Trials
47,792,196 Total Patients Enrolled
27 Trials studying Pulmonary Arterial Hypertension
3,151 Patients Enrolled for Pulmonary Arterial Hypertension
Peter J Leary, MD, PhDPrincipal InvestigatorUniversity of Washington
~12 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top